Hexachlorobenzene

CASRN 118-74-1

  • IRIS Summary (PDF) (16 pp, 129 K)
  • Status: Hexachlorobenzene is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (16 pp, 129 K) last updated: 09/26/1988

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
8 x 10-4 Hepatic Liver effects NOAEL : 8 x 10-2
mg/kg-day
100 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (16 pp, 129 K) last updated: 03/01/1991
Information reviewed but value not estimated.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (16 pp, 129 K) last updated: 03/01/1991

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Hexachlorobenzene, when administered orally, has been shown to induce tumors in the liver, thyroid and kidney in three rodent species.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (16 pp, 129 K)

Oral Slope Factor: 1.6 per mg/kg-day
Drinking Water Unit Risk: 4.6 x10 -5 per µg/L
Extrapolation Method: Linearized multistage, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma (Erturk et al., 1986)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (16 pp, 129 K)

Inhalation Unit Risk: 4.6 x10 -4 per µg/m3
Extrapolation Method: Linearized multistage, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma (Erturk et al., 1986)


You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.